Clinical trial of radiotherapy after intravenous injection of acridine orange for patients with cancer

Katsuyuki Kusuzaki, Tetsuo Takai, Hitoshi Yoshimura, Kazuya Inoue, Shigeo Takai, Nicola Baldini

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: We previously found that low-dose X-ray treatment after systemic administration of acridine orange (AO), which is known to have a low toxicity in animals, inhibited tumor growth in experimental studies using mouse osteosarcoma. In this pilot study, we planned to verify the toxicity of intravenous injection of low-dose AO in humans and investigate the anticancer effect of radiation after systemic AO administration (iAOR) for human cancer. Patients and Methods: Eight patients with terminal cancer were treated with iAOR. Results: None of the patients exhibited an adverse effect from AO injection. Three out of the five patients who received a full course of iAOR exhibited clinical or image-based responses, whereas two patients did not. Conclusion: The systemic administration of AO was confirmed not to be toxic in humans, and iAOR was suggested to be potentially effective against radioresistant cancer.

Original languageEnglish
Pages (from-to)481-489
Number of pages9
JournalAnticancer Research
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • Acridine orange
  • Autophagy
  • Cancer
  • Radiotherapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical trial of radiotherapy after intravenous injection of acridine orange for patients with cancer'. Together they form a unique fingerprint.

Cite this